Company Directory / Biotechnology
ClosedFor profitBiotechnologyZwijnaarde (Ghent), Belgium
Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies.
- Founded
- 2001 25 years ago
- Staff
- 251-500 126 on LinkedIn
- Followers
- 18k on LinkedIn
- Funding
- $499M as listed, USD
Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology… Read all
Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology. The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.
Set against six million companies
Size
251-500 people: larger than 92% of companies with a size listed. 126 people list it on LinkedIn.
Age
25 years old.
Reach
No web traffic ranking listed. 18,203 followers on LinkedIn.
What it does
BiopharmaBiotechnologyPharmaceuticalDiscoveryResearch and Drug DevelopmentNanobodies
Funding, as listed
$499M raised in total
- Rounds8
- LatestPost ipo equity, Oct 2017
- Latest amountUSD 230,000,000
- Investors11, 2 leading
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
Every detail we hold
Everything the source datasets list about Ablynx, field by field. Contact details are held but never shown.
The company
- Name
- Ablynx
- Type
- For profit
- Status
- Closed
- Founded
- 2001
- Founders
- Mark Vaeck
- Industry
- Biotechnology
- Categories
- Biopharma, Biotechnology, Pharmaceutical
- Specialities
- Discovery, Research and Drug Development, Nanobodies
Where
- City
- Zwijnaarde (Ghent)
- Country
- Belgium
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 251-500
- People on LinkedIn
- 126
- LinkedIn followers
- 18,203
Funding, as listed
- Total
- $498,783,049 USD
- Rounds
- 8
- Latest round
- Post ipo equity
- Latest round date
- Oct 2017
- Latest amount
- 230,000,000 USD
- Investors
- 11
- Lead investors
- 2
- Listing status
- delisted
About this record
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Companies like it
Biotechnology in Belgium.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,920 companies in Belgium and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.